25 Jul 2013 17:37
ADVANCED ONCOTHERAPY Plc
("Advanced Oncotherapy" or "the Company")
Issue of Equity
Advanced Oncotherapy (AIM: AVO) is pleased to announce that, at the AGM held earlier today, all resolutions were duly passed.
For further information, please visit www.advancedoncotherapy.comor contact:
Michael Sinclair, Chief Executive | Sandy Jamieson | Jon Levinson/Lucy Williams | Simon Hudson |
Advanced Oncotherapy Plc | Libertas Capital Corporate Finance Ltd | Peterhouse Corporate Finance | Tavistock Communications |
(NOMAD & Joint Broker) | (Joint Broker) | (Financial PR & IR) | |
+44 20 3617 8739 | +44 20 3697 9499 | +44 20 7469 0930 | +44 20 7920 3150 |
About Advanced Oncotherapy Plc
1. AVO is a provider of radiotherapy services that harnesses the best in modern technology. As a result, we offer cancer patients affordable access to innovative treatments with proven better health outcomes.
2. AVO's acquisition of ADAM, a company spin off from CERN (The Large Hadron Collider), focuses on the development of a proprietary radiation technology called LIGHT. This technology offers patients and providers the benefits of proton beam therapy at significantly reduced capital and running costs.
3. AVO's subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT). This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient. It is currently available in the UK from Spire Healthcare and BMI Healthcare Hospitals.
4. Through its shareholding in Advanced Proton Solutions (APS), AVO is involved in the development of the first comprehensive proton beam therapy centre in London to treat both NHS and private patients. This is the first of its kind in the UK, and will offer treatment options to UK cancer patients that have rarely been available in the past.
-ends-